KRAS and carcinoma: Type I carcinomas are characterized as diploid tumors, with estrogen-, and progesterone receptors, PTEN alterations, microsatellite instability, mutations of K-RAS, and CTNNB1. Type II carcinomas on the contrary, are often aneuploid, and show over expression of P53 and Her2/neu [2, 3].